Does quitting smoking lower age-related macular degeneration risk?

01

A historical evidence grade is not today’s whole answer

The 2014 U.S. Surgeon General report reached two different conclusions: it judged smoking a cause of neovascular and atrophic AMD, but the evidence that cessation reduces advanced AMD risk was suggestive rather than sufficient for that causal inference. Those statements address different questions and describe the evidence available to that report. ‘Smoking causes harm’ does not by itself measure the effect of quitting.

That dated grade should not be presented as if nothing has been learned since. The National Eye Institute currently lists stopping smoking among choices that may lower AMD risk, and NICE includes cessation in discussions with people who have AMD. Advice to stop is not a guarantee that a retina repairs or that an individual avoids advanced disease.

[1][3][4]

02

What the later genetic study adds—and why 0.66 is not your multiplier

A 2021 two-sample Mendelian-randomization study used genetic variants associated with smoking behaviour, rather than assigning people to a cessation programme. For advanced AMD, the outcome dataset included 16,144 cases and 17,832 controls. The cessation instrument used 23 variants from a separate study of 547,219 European participants, comparing the genetic tendency toward former rather than current smoking.

The main analysis found lower odds of advanced AMD with genetically predicted cessation: OR 0.66 (95% confidence interval 0.50–0.87) per one-standard-deviation increase on the log-odds scale of that genetic prediction. This statistical unit is not ‘one person quits’ or ‘one year smoke-free’. Odds are the probability of the outcome divided by the probability of not having it; an odds ratio compares those ratios. This is not a comparison of absolute probabilities or a way to calculate your personal probability from the genetic estimate. It cannot become ‘quitting cuts everyone’s risk by 34%’.

The authors explicitly caution that a Mendelian-randomization estimate tests a causal hypothesis better than it predicts the effect of a clinical intervention at a specific time. Genetic variants may act through other pathways, residual pleiotropy cannot be fully excluded, and the largely European data limit transfer to other populations. This supports possible benefit without supplying a personal timeline. Separate analyses of neovascular AMD and geographic atrophy found no statistically clear association with cessation. That does not rule out an effect: the smaller subtype samples limited statistical power.

[2]

03

Check which eye outcome a headline means

AMD concerns the macula, the central part of the retina, not the cloudy lens of cataract. Early AMD, development of advanced AMD, progression of diagnosed disease and changes in usable vision are different outcomes. An estimate for advanced AMD cannot automatically answer whether an existing eye’s visual acuity improves.

Similarly, former-smoker versus never-smoker comparisons retain differences in prior exposure and do not equal a quit-versus-continue experiment. Age, genetics, accumulated smoking and outcome definitions matter. A ‘10-year reset’ or ‘20-year reset’ headline needs its own population, comparator and endpoint; it is not a universal anniversary rule. Nor are results from supplements or injections evidence of a smoking-cessation effect.

[1][2][3]

04

Keep tobacco support and retinal care connected, not interchangeable

For known AMD or concerns about vision, a qualified eye-care professional can explain the relevant stage and care plan. A useful question is: ‘What outcome does this evidence concern, and what does it leave unanswered about my existing eye condition?’ New or concerning vision changes need clinical assessment, not attribution to quitting or a wait for the predicted benefit. Stage, examinations, monitoring and treatment choices are not decided here.

In England, NHS local stop-smoking services provide a separate support route. This page does not collect vision, genetic results or smoking history, and it does not recommend a supplement or alter an injection schedule. Limited precision about AMD does not mean quitting is pointless, and successful quitting does not replace eye care.

[3][4][5]

05

What to keep in mind

• Do not erase later evidence with a 2014 grade.
• A genetic estimate is not the effect of quitting at a chosen date.
• Clear cessation advice and uncertain personal size can coexist.
• Retinal care remains a separate necessary conversation.